JP2022544760A5 - - Google Patents

Info

Publication number
JP2022544760A5
JP2022544760A5 JP2022507875A JP2022507875A JP2022544760A5 JP 2022544760 A5 JP2022544760 A5 JP 2022544760A5 JP 2022507875 A JP2022507875 A JP 2022507875A JP 2022507875 A JP2022507875 A JP 2022507875A JP 2022544760 A5 JP2022544760 A5 JP 2022544760A5
Authority
JP
Japan
Prior art keywords
cys
scfv
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022507875A
Other languages
English (en)
Japanese (ja)
Other versions
JP7797373B2 (ja
JP2022544760A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/046303 external-priority patent/WO2021030657A1/en
Publication of JP2022544760A publication Critical patent/JP2022544760A/ja
Priority to JP2025042288A priority Critical patent/JP2025094049A/ja
Publication of JP2022544760A5 publication Critical patent/JP2022544760A5/ja
Application granted granted Critical
Publication of JP7797373B2 publication Critical patent/JP7797373B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022507875A 2019-08-15 2020-08-14 改善された単鎖可変断片のための材料及び方法 Active JP7797373B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025042288A JP2025094049A (ja) 2019-08-15 2025-03-17 改善された単鎖可変断片のための材料及び方法

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US201962887519P 2019-08-15 2019-08-15
US201962887527P 2019-08-15 2019-08-15
US201962887524P 2019-08-15 2019-08-15
US201962887529P 2019-08-15 2019-08-15
US201962887514P 2019-08-15 2019-08-15
US62/887,524 2019-08-15
US62/887,514 2019-08-15
US62/887,519 2019-08-15
US62/887,529 2019-08-15
US62/887,527 2019-08-15
US201962946877P 2019-12-11 2019-12-11
US201962946865P 2019-12-11 2019-12-11
US201962946886P 2019-12-11 2019-12-11
US201962946882P 2019-12-11 2019-12-11
US201962946897P 2019-12-11 2019-12-11
US62/946,865 2019-12-11
US62/946,882 2019-12-11
US62/946,897 2019-12-11
US62/946,877 2019-12-11
US62/946,886 2019-12-11
PCT/US2020/046303 WO2021030657A1 (en) 2019-08-15 2020-08-14 Materials and methods for improved single chain variable fragments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025042288A Division JP2025094049A (ja) 2019-08-15 2025-03-17 改善された単鎖可変断片のための材料及び方法

Publications (3)

Publication Number Publication Date
JP2022544760A JP2022544760A (ja) 2022-10-21
JP2022544760A5 true JP2022544760A5 (enExample) 2025-09-17
JP7797373B2 JP7797373B2 (ja) 2026-01-13

Family

ID=72243247

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022507875A Active JP7797373B2 (ja) 2019-08-15 2020-08-14 改善された単鎖可変断片のための材料及び方法
JP2025042288A Pending JP2025094049A (ja) 2019-08-15 2025-03-17 改善された単鎖可変断片のための材料及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025042288A Pending JP2025094049A (ja) 2019-08-15 2025-03-17 改善された単鎖可変断片のための材料及び方法

Country Status (19)

Country Link
US (2) US11787875B2 (enExample)
EP (1) EP4013783A1 (enExample)
JP (2) JP7797373B2 (enExample)
KR (1) KR20220062494A (enExample)
CN (1) CN114258400A (enExample)
AU (1) AU2020328049A1 (enExample)
BR (1) BR112022002540A2 (enExample)
CA (1) CA3148121A1 (enExample)
CO (1) CO2022001222A2 (enExample)
CR (1) CR20220054A (enExample)
DO (1) DOP2022000032A (enExample)
EC (1) ECSP22011199A (enExample)
IL (1) IL290436A (enExample)
JO (1) JOP20220035A1 (enExample)
MX (1) MX2022001799A (enExample)
PE (1) PE20220299A1 (enExample)
PH (1) PH12022550348A1 (enExample)
TW (1) TW202120537A (enExample)
WO (1) WO2021030657A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3164226A1 (en) * 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
CN117098781A (zh) * 2021-03-24 2023-11-21 詹森生物科技公司 靶向cd22和cd79b的抗体
WO2023089587A1 (en) * 2021-11-22 2023-05-25 Janssen Biotech, Inc. Compositions comprising enhanced multispecific binding agents for an immune response
WO2023152581A1 (en) 2022-02-09 2023-08-17 Janssen Biotech, Inc. Method of treating cancer with psmaxcd3 antibody
US12365743B2 (en) * 2022-02-23 2025-07-22 Xencor, Inc. Anti-CD28 x anti-PSMA antibodies
CA3263779A1 (en) 2022-08-05 2024-02-08 Janssen Biotech, Inc. CD98 LINKAGE CONSTRUCTIONS FOR THE TREATMENT OF BRAIN TUMORS
MA71684A (fr) 2022-08-05 2025-05-30 Janssen Biotech, Inc. Protéines de liaison de récepteur de transferrine pour traitement de tumeurs cérébrales
AR133412A1 (es) 2023-07-30 2025-09-24 Janssen Biotech Inc Moléculas que se unen a la calreticulina mutante y usos de estas
IL326401A (en) 2023-08-07 2026-04-01 Janssen Biotech Inc Stabilized CD3 antigen binding materials and methods of using them
KR20260051064A (ko) * 2023-08-07 2026-04-15 얀센 바이오테크 인코포레이티드 Gucy2c 항체 및 이의 용도
AU2024319838A1 (en) 2023-08-07 2025-02-13 Janssen Biotech, Inc. Enpp3 and cd3 binding agents and methods of use thereof
US20250122299A1 (en) 2023-08-28 2025-04-17 Xencor, Inc. ANTI-CD20 x ANTI-CD28 COMBINATION THERAPIES
WO2025088587A1 (en) * 2023-10-27 2025-05-01 Janssen Biotech, Inc. Compositions comprising enhanced multispecific binding agents for an immune response
TW202540161A (zh) 2023-11-21 2025-10-16 美商健生生物科技公司 治療骨髓增生性腫瘤之方法
WO2025126102A1 (en) 2023-12-12 2025-06-19 Janssen Biotech, Inc. Enpp3 × cd3 bispecific antibodies and use thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025172924A1 (en) 2024-02-15 2025-08-21 Janssen Biotech, Inc. Anti-transferrin receptor compositions and methods thereof
WO2025243243A1 (en) 2024-05-24 2025-11-27 Janssen Biotech, Inc. Bispecific antibody targeting emr2 (cd312) and the t-cell receptor trbv19
WO2025251110A1 (en) * 2024-06-03 2025-12-11 Selvax Pty Ltd Anti-cd40 antibody il-2 fusion proteins
WO2025259749A1 (en) * 2024-06-12 2025-12-18 Amgen Inc. Stable single-chain variable fragments
WO2026035888A1 (en) 2024-08-06 2026-02-12 Janssen Biotech, Inc. Methods and compositions for modulating beta chain mediated immunity
WO2026055669A2 (en) 2024-09-09 2026-03-12 Xencor, Inc. Anti-tl1a x anti-il23 antibodies

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
CA2646508A1 (en) * 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008120101A2 (en) 2007-04-02 2008-10-09 Philogen S.P.A. The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AU2009270405B2 (en) * 2008-06-30 2014-06-05 Esbatech, An Alcon Biomedical Research Unit Llc Functionalized polypeptides
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
JP5764127B2 (ja) 2009-08-17 2015-08-12 ロシュ グリクアート アーゲー 標的化イムノコンジュゲート
WO2011030107A1 (en) * 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
JP2013514788A (ja) * 2009-12-23 2013-05-02 アビペップ ピーティーワイ リミテッド イムノコンジュゲート及びその作製方法２
GB201005064D0 (en) * 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
CN103068846B9 (zh) * 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
TWI743461B (zh) * 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
BR112014010580B1 (pt) 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
WO2013175678A1 (ja) * 2012-05-24 2013-11-28 パナソニック株式会社 ヒト心筋由来トロポニンｉに特異的にかつ速やかに結合できる変異体タンパク質
MX366910B (es) 2013-03-15 2019-07-30 Janssen Biotech Inc Metodos de fabricacion para controlar el contenido de lisina c-terminal, galactosa y acido sialico en proteinas recombinantes.
RU2016132863A (ru) * 2014-01-15 2018-02-20 Займворкс Инк. БИСПЕЦИФИЧЕСКИЕ CD3 и CD19 АНТИГЕНСВЯЗЫВАЮЩИЕ КОНСТРУКЦИИ
US10882918B2 (en) 2016-09-30 2021-01-05 Hoffmann-La Roche Inc. Bispecific T cell activating antigen binding molecules
WO2019060695A1 (en) 2017-09-22 2019-03-28 Kite Pharma, Inc. CHIMERIC POLYPEPTIDES AND USES THEREOF
GB201721421D0 (en) * 2017-12-20 2018-01-31 Ucl Business Plc Chimeric antigen receptor

Similar Documents

Publication Publication Date Title
JP2022544760A5 (enExample)
US12152076B2 (en) Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10793621B2 (en) Nucleic acid encoding dual Fc antigen binding proteins
JP7566766B2 (ja) 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体
JP7450535B2 (ja) 単一特異性抗体から多重特異性抗体を生成させるための方法
JP2022544760A (ja) 改善された単鎖可変断片のための材料及び方法
CA2824824A1 (en) Monovalent antigen binding proteins
JP7645799B2 (ja) ヘテロダイマー抗体の作製方法
CA2761233A1 (en) Tri- or tetraspecific antibodies
WO2013164325A1 (en) Multispecific antigen binding proteins
WO2025245176A1 (en) Multispecific antibody constructs
JP2026506906A (ja) 抗Ｖβ１７／抗ＣＤ１２３二重特異性抗体
WO2025108310A1 (zh) 通过重组反应制备异源多聚体的方法
WO2026050570A1 (en) Engineered protein constructs targeting siglec-8 and cd117
HK40031028A (en) Method for generating multispecific antibodies from monospecific antibodies
HK40031028B (zh) 从单特异性抗体生成多特异性抗体的方法
HK1189904A (en) Antigen binding proteins